Thessaloniki

• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai … Ended
  2024-516061-36-00 4 2022-07-28 Newly diagnosed patients with multiple myeloma and severe renal impair
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapy Ended
  2023-508840-22-00 5 2022-06-27 Atypical hemolytic uremic syndrome
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight … Ended
  2023-509668-11-00 6 2022-06-15 Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended
  2024-510872-18-00 4 2022-05-09 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult … Ended
  2024-515832-59-00 5 2022-05-03 Bullous Pemphigoid
• A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with … Ended
  2022-502752-31-00 11 2022-04-29 Non-small cell lung cancer
• This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromeg … Ended
  2024-511924-15-00 5 2022-04-29 Acromegaly
• A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetux … Ended
  2024-513082-39-00 4 2022-04-26 Locally Advanced Head & Neck Squamous Cell Carcinoma
• Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended
  2022-502802-34-00 5 2022-04-05 Dravet and Lennox-Gastaut Syndromes
• A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON) Ended
  2024-515743-27-00 5 2022-04-04 Childhood Interstitial Lung Disease
• A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended
  2024-511560-93-00 5 2022-03-29 Schizophrenia
• ​​Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)​ Ended
  2024-511187-81-00 5 2022-03-28 Colorectal Cancer (CRC)

Showing 577–600 of 652 trials